Question special

Many of the "new" brand name drugs promoted by pharmaceutical companies are nearly identical to ones already on the market. These "me too" drugs typically come with a steep price tag, driving up healthcare costs when they compete with available generics. Australian policy prohibits the addition of "me too" drugs to insurance formularies unless they demonstrate improved outcomes or lower costs. What would be the impact if the US were to adopt such a policy? Do you think the FDA should change its approval criteria for "addition to class" drugs?